Adocia SA (EPA:ADOC)

Market Cap	71.38M -50.7%
Revenue (ttm)	3.85M -68.3%
Net Income	-16.59M
EPS	-0.93
Shares Out	19.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,275
Open	3.774
Previous Close	3.800
Day's Range	3.620 - 3.774
52-Week Range	3.610 - 12.400
Beta	0.27
Analysts	Buy
Price Target	9.70 (+165.9%)
Earnings Date	Sep 24, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combinati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 73
• Stock Exchange: Euronext Paris
• Ticker Symbol: ADOC

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for ADOC stock is "Buy." The 12-month stock price target is €9.70, which is an increase of 165.90% from the latest price.

Price Target

€9.70

(165.90% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error